A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma

Anti-angiogenic therapy, targeting vascular endothelial growth factor (VEGF)-A/VEGF receptors (VEGFRs), is beneficial for tumor growth prevention in a malignant glioma. A simultaneous blockade using both bevacizumab (Bev), which targets circulating VEGF-A, and a multi-kinase inhibitor on VEGFRs was...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, Ryota, Morimoto, Yukina, Sato, Mizuto, Hikichi, Tetsuro, Yoshida, Kazunari, Toda, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564945/
https://www.ncbi.nlm.nih.gov/pubmed/32887369
http://dx.doi.org/10.3390/vaccines8030498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564945/
https://www.ncbi.nlm.nih.gov/pubmed/32887369
http://dx.doi.org/10.3390/vaccines8030498

Ejemplares similares